Brazil pharma growth set for 21.5% in 2008

12 October 2008

Brazil's pharmaceutical market, which regularly tops the IMS Health Retail Drug Monitor's growth list of 13 leading countries (Marketletters passim), is set to expand by 21.5% this year according to data from Business Monitor International, up from last year's still impressive 17%.

Part of the growth is attributable to currency fluctuations, with 7.7% remaining in local currency (the real). The main factors in the country's pharmaceutical market acceleration are a dynamic generic drug sector, government health care spending increases and a steady economic performance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight